Ageless Biotech
Advancing Biologic Medicine
Ageless Biotech (ABT) is in the development of adipose based stemcell products through a process know as Stromal Vascular Fraction (SVF) and discardable, minimally manipulated fetal tissue based regenerative medicine biologics to address all forms of Osteoarthritis via intra-articular procedures in cooperation with leading scientists and medical professionals.
Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.
We believe that the formation of life itself is contained within after birth tissues and the science indicates that there may even be a greater abondance of MSC's and Stromal Stem Cells that are the building blocks of every tissue in the human body stored in adipose. ABT believes that it is morally, religiously and politically acceptable to use afterbirth and adipose derived human cells that would be considered discardable in every country. Furthermore, we believe this to be the right course to addressing problems that a vast majority of the population will face at some point during their lifespan.
This tissue is rich in young pluripotent stem cells, multipotent stem cells, stromal cells, extracellular matrices, exosomes, hyaluronic acid, various other molecules, proteins, natural signaling mechanisms and is the symphony responsible for the formation of life itself.
In combination, with proprietary processing and intellectual property ABT has an established a target date of first quarter 2022 t for Phase 2 Clinical Trials.
“Medical care for osteoarthritis patients in the United States costs $185.5 billion a year, according to a new study. Of that amount, insurers pay $149.4 billion while patients pay $36.1 billion in out-of-pocket costs.” Nov 30, 2015"
https://www.medicinenet.com/script/main/art.asp?articlekey=108110
Osteoarthritis has an annual global economic impact of more than $1 Trillion. https://www.researchgate.net/publication/232321524_The_Global_Economic_Cost_of_Osteoarthritis_How_the_UK_Compares
Patent Pending Technology
In combination with proprietary, patent-pending device intellectual property ABT uses pre-established Innovative Proprietary processing Technologies to extract, manufacture and deliver a product with maximum biologic potency. We believe the Ageless Biotech process will revolutionize the biologics industry greatly impacting the future of regenerative healthcare.
Contact Us
"Big results require big ambitions"
Heraclitus
